Search - tctmd.com

Displaying 41 - 60 of 106

Sort: Relevancy | Date

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Michael O'Riordan

August 19, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Features

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

Marcus A. Banks

August 15, 2019

News Daily News

Earlier Care, More Data Needed to Increase Treatment Success in Tricuspid Regurgitation

Yael L. Maxwell

August 07, 2019

News Features

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Yael L. Maxwell

August 02, 2019

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Todd Neale

July 29, 2019

News Industry News

Dassault Systèmes and the FDA Extend Collaboration to Inform Cardiovascular Device Review Process and Accelerate Access to New Treatments

July 24, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Industry News

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

July 01, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Industry News

CRF And VEITHsymposium Announce an Alliance Between Transcatheter Cardiovascular Therapeutics (TCT) and VEITHsymposium

June 19, 2019

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

Presentation TVT 2019

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial

Presenter: Philippe Pibarot

June 14, 2019

News Conference News TVT 2019

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Shelley Wood

June 13, 2019

Presentation TVT 2019

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

Highlights From the PARTNER 3 Low-Risk Trial

Presenter: Michael Mack

June 13, 2019

Presentation TVT 2019

The PARTNER 3 Low-Risk Randomized Trial

Presenter: Susheel Kodali

June 13, 2019

News Conference News SCAI 2019

TAVR Operators: Can One Do It All or Are Two Still Justified?

Yael L. Maxwell

June 04, 2019

Advertisement

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

FDA Expands TAVR Indication to Low-Risk Patients

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

Earlier Care, More Data Needed to Increase Treatment Success in Tricuspid Regurgitation

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Dassault Systèmes and the FDA Extend Collaboration to Inform Cardiovascular Device Review Process and Accelerate Access to New Treatments

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

CRF And VEITHsymposium Announce an Alliance Between Transcatheter Cardiovascular Therapeutics (TCT) and VEITHsymposium

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Highlights From the PARTNER 3 Low-Risk Trial

The PARTNER 3 Low-Risk Randomized Trial

TAVR Operators: Can One Do It All or Are Two Still Justified?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content